31
6
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T81913 |
LSD
|
||
LSD为光免疫研究中使用的酞菁偶联物。 | |||
T31361 |
Deethyl-LSD
LAE 32,Lysergic acid ethylamide,LAE-32,N-Ethyllysergamide,LAE32 |
||
Deethyl-LSD is reported to have some LSD-like effects but is weaker and shorter-lasting, with an active dose reported to be between 0.5 and 1.5 milligrams. | |||
T2315 |
GSK-LSD1 dihydrochloride
GSK-LSD1 (hydrochloride),GSK-LSD1 2HCl |
Histone Demethylase | Chromatin/Epigenetic |
GSK-LSD1 dihydrochloride (GSK-LSD1 2HCl) 是一种特异性不可逆的 LSD1 抑制剂(IC50: 16 nM)。GSK-LSD1 dihydrochloride 对 LSD1 的选择性是其他密切相关的 FAD 利用酶(即 MAO-A、LSD2、MAO-B)的 1000 倍以上。 | |||
T67871 |
LSD1-IN-24
|
Histone Demethylase; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Immunology/Inflammation |
LSD1-IN-24 是一种具有选择性和有效性的 LSD1 抑制剂,IC50 值为 0.247 μM。LSD1-IN-24 可诱导 PD-L1 的表达,加强 T 细胞杀伤反应,可用于癌症相关疾病。 | |||
T83966 |
LSD1-IN-30
|
Histone Demethylase | Chromatin/Epigenetic |
LSD1-IN-30 是赖氨酸特异性脱甲基酶 1 (LSD1) 抑制剂,具有抗癌活性,可用于研究小细胞肺癌和急性髓细胞白血病。 | |||
T63140 |
LSD1-IN-20
|
Histone Demethylase | Chromatin/Epigenetic |
LSD1-IN-20 是一种有效的 LSD1/G9a 双重抑制剂,其 Ki 值分别为 0.44 和 0.68 μM。LSD1-IN-20 在体外实验中对 THP-1 白血病细胞和 MDA-MB-231 乳腺癌细胞显示出抗增殖活性,72 h 时 IC50 分别为 0.51 和 1.60 μM。 | |||
T77635 |
LSD1-IN-27
|
Histone Demethylase; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Immunology/Inflammation |
LSD1-IN-27 是一种高效的 LSD1 抑制剂 ,IC50 值为 13 nM。LSD1-IN-27 对胃癌细胞的干细胞性和迁移有抑制作用。LSD1-IN-27 对 BGC-823 和 MFC 细胞中 PD-L1 的表达有抑制作用。LSD1-IN-27 可增强对胃癌的 T 细胞免疫反应。 | |||
T36625 |
LSD1/HDAC6-IN-1
LSD1/HDAC6-IN-1 |
||
LSD1/HDAC6-IN-1 is an orally active compound that functions as a dual inhibitor, targeting lysine specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6). This compound demonstrates promising anti-tumor activity and is particularly valuable for research focused on multiple myeloma (MM) [1]. | |||
T11882 |
Pulrodemstat benzenesulfonate
LSD1-IN-7 benzenesulfonate,CC-90011 benzenesulfonate |
Histone Demethylase | Chromatin/Epigenetic |
Pulrodemstat benzenesulfonate (CC-90011 benzenesulfonate) 是一种有效的口服活性赖氨酸特异性去甲基化酶 1 (LSD1) 抑制剂,IC50为 0.25 nM,具有抗癌活性。它诱导急性髓细胞性白血病和小细胞肺癌细胞分化,对 LSD2、MOA-A 和 MAO-B 的酶抑制作用较小。 | |||
T11881 | LSD1-IN-6 | Histone Demethylase | Chromatin/Epigenetic |
LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-6 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 123 nM. | |||
T11880 |
LSD1-IN-5
|
Histone Demethylase | Chromatin/Epigenetic |
LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1. LSD1-IN-5 is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC50 of 121 nM. | |||
T60362 | LSD1-IN-22 | ||
LSD1-IN-22 是一种有效的赖氨酸特异性去甲基化酶 1 (LSD1) 抑制剂(Ki= 98 nM)。LSD1-IN-22 对某些癌细胞具有抗增殖活性。 | |||
T60381 |
LSD1-IN-12
|
||
LSD1-IN-12 (compound 2) 是有效的 LSD1抑制剂,Ki 值分别为 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), 和 3.5 μM (MAO-B)。 | |||
T62674 | LSD1-IN-21 | ||
LSD1-IN-21 是一种有效的、具有血脑屏障通透性的 LSD1 (赖氨酸特异性去甲基化酶-1) 抑制剂 (IC50: 0.956 μM)。LSD1-IN-21 能够明显减少促炎细胞因子 TNF-α,表现出良好的抗癌和抗炎效果。 | |||
T62099 |
LSD1-IN-13
|
||
LSD1-IN-13 (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM),也能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T63716 | LSD1-IN-18 | ||
LSD1-IN-18 是有效的、非共价的、选择性的 LSD1 抑制剂 (Ki:0.156 μM; KD: 0.075 μM)。LSD1-IN-18 在 THP-1 白血病细胞和 MDA-MB-231 乳腺癌细胞中表现出抗增殖效果,其IC50(72 h) 分别为 0.16 和 0.21 μM。 | |||
T74855 | LSD1-IN-25 | Histone Demethylase | Chromatin/Epigenetic |
LSD1-IN-25(Compound 9j)是一种高效、选择性及口服活性的LSD1抑制剂,具有46 nM的IC50(Ki值为30.3 nM),并能够诱导癌细胞的凋亡(apoptosis)。 | |||
T61405 | LSD1-IN-14 | ||
LSD1-IN-14, a powerful and specific inhibitor of LSD1 (with an IC50 value of 0.89 μM), effectively suppresses the growth of A549 and THP-1 cells and promotes the apoptosis of tumor cells [1]. | |||
T82254 |
GSK-LSD1
|
Histone Demethylase | Chromatin/Epigenetic |
GSK-LSD1是一种LSD1抑制剂,能够降低肥胖小鼠模型的摄食量和体重,同时提升胰岛素敏感性与血糖控制。此外,GSK-LSD1对NAFLD也有改善作用,并能抑制COVID-19患者PBMC中SARS-CoV-2诱导的细胞因子释放。GSK-LSD1对抑制癌症的生长与转移也显示出潜在效果。 | |||
T61021 | LSD1-IN-16 | ||
LSD1-IN-16 (compound 4b) 是 LSD1的有效抑制剂,可抑制 LSD1-CoREST、MAO-A 和 MAO-B,IC50值分别为 0.015、0.024 和 0.366 μM。LSD1-IN-16 在前列腺癌 LNCaP 细胞中表现出细胞生长阻滞,IC50值为 15.2 μM。 | |||
T63920 | LSD1-IN-19 | ||
LSD1-IN-19 (compound 29) 是一种选择性的、有效的、非共价的 LSD1 抑制剂 (Ki: 0.108 μM, KD: 0.068 μM)。LSD1-IN-19 在 THP-1 白血病细胞和 MDA-MB-231 乳腺癌细胞中具有抗增殖效果,其72h 的IC50值分别为 0.17 和 0.40 μM。 | |||
T74858 | LSD1-IN-26 | ||
LSD1-IN-26(compound 12u)是一种对LSD1具有高效抑制作用的化合物,表现出25.3 nM的IC50值。该化合物对MAO-A和MAO-B亦有一定抑制效果,其IC50值分别为1234.57 nM和3819.27 nM。此外,LSD1-IN-26能够显著促进MGC-803细胞的凋亡,适用于胃癌的研究领域。 | |||
T61022 | LSD1-IN-17 | ||
LSD1-IN-17 (compound 5b) 是 LSD1的有效抑制剂,可抑制LSD1-CoREST、MAO-A 和MAO-B,IC50值分别为 0.005、0.028 和 0.820 μM。LSD1-IN-17 在前列腺癌 LNCaP 细胞中表现出细胞生长阻滞,IC50值为 17.2 μM。 | |||
T60941 | LSD1-IN-15 | ||
LSD1-IN-15 (compound 1b) 是一种有效的 LSD1抑制剂,可抑制 LSD1-CoREST、MAO-A 和 MAO-B,IC50值分别为 0.149、0.028 和 0.327 μM。LSD1-IN-15 显示前列腺癌 LNCaP 细胞中的细胞生长停滞,IC50值为 9.9 μM。 | |||
T62679 |
LSD1-IN-13 hydrochloride
|
||
LSD1-IN-13 hydrochloride (compound 7e) 是一种口服具有活力的 LSD1 抑制剂 (IC50: 24.43 nM)。LSD1-IN-13 hydrochloride 能够激活 CD86 表达 (EC50: 470 nM)。LSD1-IN-13 hydrochloride 可以诱导 AML (急性髓系白血病) 细胞系分化。 | |||
T78888 | LSD1-UM-109 | Histone Demethylase | Chromatin/Epigenetic |
LSD1-UM-109为一强效可逆LSD1抑制剂,其IC50为3.1 nM。在MV4;11急性白血病细胞系中,该化合物抑制细胞生长,IC50值达0.6 nM,在H1417小细胞肺癌细胞系中,IC50值为1.1 nM。 | |||
T60361 | LSD1/2-IN-4 | ||
LSD1/2-IN-4 是一种 PCPA 衍生物,是 LSD1 和 LSD2 的抑制剂。LSD1/2-IN-4 对 LSD1 和 LSD2 具有抑制作用,其Ki 值分别为 0.11 μM 和 130 μM。LSD1/2-IN-4 可用于多种癌症的研究,如 T 细胞急性淋巴细胞白血病 (TALL) 。 | |||
T60360 | LSD1/2-IN-3 | ||
LSD1/2-IN-3 是赖氨酸特异性去甲基化酶 1 (LSD1) 的选择性抑制剂,Ki 值是 11 nM,而对LSD2的 Ki 值为 7 μM。LSD1在肿瘤干细胞中异常表达,LSD1/2-IN-3 能够抑制LSD1活性和癌细胞增殖。 | |||
T62818 | LSD1/ER-IN-1 | ||
LSD1/ER-IN-1 (compound 11g) 是一种有效的 ER 和 LSD1 抑制剂,能够作用于 LSD1 (IC50: 1.55 μM)。LSD1/ER-IN-1 能够高亲和力的选择 Erα 蛋白,α/β 比为 7.11。LSD1/ER-IN-1 对 MCF-7 乳腺癌细胞表现出良好的抗增殖效果 (IC50: 8.79 μM)。 | |||
T32906 |
LSZ
|
||
LSZ is an analog of LSD. | |||
T36627 |
Lysine-specific Demethylase Inhibitor (1C) (hydrochloride)
|
||
Lysine-specific demethylase inhibitor (1C) (LSD inhibitor (1C)) is an inhibitor of LSD1, a repressive demethylase selective for histone H3 lysine 4 (H3K4).1,2LSD inhibitor (1C) inhibits LSD1 activity by 85.9% when used at a concentration of 10 μM.1It increases the level of H3K4 methylation, including H3K4me1 and H3K4me2 but not H3K9me2 levels, in HCT116 human colon carcinoma cells.2LSD inhibitor (1C) also induces re-expression of the Wnt signaling pathway proteins secreted frizzle-related protei... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03056 |
LSD1 Protein, Human, Recombinant (His & GST)
BHC110,LSD1,KDM1,AOF2,lysine (K)-specific demethyla... |
Human | Baculovirus Insect Cells |
LSD1 belongs to the flavin monoamine oxidase family. It contains 1 SWIRM domain and is a component of an RCOR/GFI/LSD1/HDAC complex. LSD1 interacts directly with GFI1 and GFI1B. LSD1 specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 through a FAD-dependent oxidative reaction. When forming a complex with an androgen receptor (and possibly other nuclear hormone receptors), LSD1 changes its substrates to H3K9me2. Thus LSD1 is considered to act as a coactivator or a corepressor. It may play... | |||
TMPH-01213 |
DNASE1L3 Protein, Human, Recombinant (His)
DNase I homolog protein DHP2,DNAS1L3,DNase I-like 3,Deoxyrib... |
Human | Baculovirus Insect Cells |
Has DNA hydrolytic activity. Is capable of both single- and double-stranded DNA cleavage, producing DNA fragments with 3'-OH ends. Can cleave chromatin to nucleosomal units and cleaves nucleosomal and liposome-coated DNA. Acts in internucleosomal DNA fragmentation (INDF) during apoptosis and necrosis. The role in apoptosis includes myogenic and neuronal differentiation, and BCR-mediated clonal deletion of self-reactive B cells. Is active on chromatin in apoptotic cell-derived membrane-coated mic... | |||
TMPH-01212 |
DNASE1L3 Protein, Human, Recombinant (His & Myc)
LSD,Liver and spleen DNase,Deoxyribonuclease I-like... |
Human | E. coli |
Has DNA hydrolytic activity. Is capable of both single- and double-stranded DNA cleavage, producing DNA fragments with 3'-OH ends. Can cleave chromatin to nucleosomal units and cleaves nucleosomal and liposome-coated DNA. Acts in internucleosomal DNA fragmentation (INDF) during apoptosis and necrosis. The role in apoptosis includes myogenic and neuronal differentiation, and BCR-mediated clonal deletion of self-reactive B cells. Is active on chromatin in apoptotic cell-derived membrane-coated mic... | |||
TMPH-01214 |
DNASE1L3 Protein, Human, Recombinant
DHP2,Deoxyribonuclease I-like 3,Deoxyribonuclease gamma,DNas... |
Human | E. coli |
Has DNA hydrolytic activity. Is capable of both single- and double-stranded DNA cleavage, producing DNA fragments with 3'-OH ends. Can cleave chromatin to nucleosomal units and cleaves nucleosomal and liposome-coated DNA. Acts in internucleosomal DNA fragmentation (INDF) during apoptosis and necrosis. The role in apoptosis includes myogenic and neuronal differentiation, and BCR-mediated clonal deletion of self-reactive B cells. Is active on chromatin in apoptotic cell-derived membrane-coated mic... | |||
TMPH-03560 |
lsdA Protein, S. aureus, Recombinant (His & Myc)
|
Staphylococcus aureus | E. coli |
lsdA Protein, S. aureus, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 35.1 kDa and the accession number is Q6GA85. | |||
TMPH-03561 |
lsdB Protein, S. aureus, Recombinant (His & SUMO)
|
Staphylococcus aureus | E. coli |
Cell wall-anchored surface receptor that extracts heme from oxidized metHb to enable growth on hemoglobin as a sole iron source. Rapidly extracts heme from hemoglobin and transfers it to IsdA or IsdC, which then relays it to the membrane transporter/IsdEF for internalization. Promotes also resistance to hydrogen peroxide and killing by neutrophils. lsdB Protein, S. aureus, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is ... |